Related references
Note: Only part of the references are listed.The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
Suzanne Trudel et al.
BLOOD CANCER JOURNAL (2019)
Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase
Ian J. Huggins et al.
MOLECULES (2019)
Antibodies to watch in 2019
Helene Kaplon et al.
MABS (2019)
Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues
Dobeen Hwang et al.
CELL CHEMICAL BIOLOGY (2019)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Facile Synthesis, Geometry, and 2′-Substituent-Dependent in Vivo Activity of 5′-(E)- and 5′-(Z)-Vinylphosphonate-Modified siRNA Conjugates
Rubina Giare Parmar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Advanced siRNA Designs Further Improve In Vivo Performance of GaINAc-siRNA Conjugates
Donald J. Foster et al.
MOLECULAR THERAPY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
Suzanne Trudel et al.
LANCET ONCOLOGY (2018)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates
Jayaprakash K. Nair et al.
NUCLEIC ACIDS RESEARCH (2017)
Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates
Alex R. Nanna et al.
NATURE COMMUNICATIONS (2017)
Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown
Nicole Baeumer et al.
NATURE PROTOCOLS (2016)
9 5′-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates
Rubina Parmar et al.
CHEMBIOCHEM (2016)
Immune Therapies in Multiple Myeloma
Shaji K. Kumar et al.
CLINICAL CANCER RESEARCH (2016)
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Tsukasa Sugo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Structural Analysis of Human Argonaute-2 Bound to a Modified siRNA Guide
Nicole T. Schirle et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)
CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies
Matthew R. Gardner et al.
JOURNAL OF VIROLOGY (2016)
Role of Wnt/β-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells
Nan Su et al.
ONCOLOGY LETTERS (2016)
Antibody-Mediated Delivery of Anti-KRAS-siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Sebastian Baeumer et al.
CLINICAL CANCER RESEARCH (2015)
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Jonathan E. Zuckerman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
Trinna L. Cuellar et al.
NUCLEIC ACIDS RESEARCH (2015)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Site-Specific Antibody-Polymer Conjugates for siRNA Delivery
Hua Lu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Association of β-catenin, Wnt1, Smad4, Hoxa9, and Bmi-1 with the prognosis of esophageal squamous cell carcinoma
Jin Lv et al.
MEDICAL ONCOLOGY (2012)
Expanding the Concept of Chemically Programmable Antibodies to RNA Aptamers: Chemically Programmed Biotherapeutics
Ulrich Wuellner et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2010)
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al.
NATURE BIOTECHNOLOGY (2010)
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
Hiroshi Ikeda et al.
CLINICAL CANCER RESEARCH (2009)
Antibody-Mediated Targeting of siRNA via the Human Insulin Receptor Using Avidin-Biotin Technology
Chun-Fang Xia et al.
MOLECULAR PHARMACEUTICS (2009)
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice
Priti Kumar et al.
CELL (2008)
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1
Dan Peer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
EW Song et al.
NATURE BIOTECHNOLOGY (2005)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy
C Rader et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task
A Karlstrom et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
